American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM)

By AANEMMedicine Health & Fitness

American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) episodes

April 15, 2014 Improving Referring Physicians' Understanding of EMG Reports When Qualifying Radiculopathies
Electromyographic (EMG) reporting of radiculopathies is not standardized, and the terminology used in reports can be misinterpreted by referring physicians. Physicians who refer patients for EMG studies at the Mayo Clinic were surveyed about their understanding of 6 different EMG interpretations of an S1 radiculopathy. Of 45 responders, the terms “acute, active,” “chronic, inactive,” and “old” were interpreted consistently by 95%, 98%, and 84% of responders, respectively. Physicians had the most difficulty understanding the meaning of “chronic” in isolation, “chronic, active,” or “old with uncompensated denervation.” These findings suggest a need to educate referring physicians on the meaning of the terms used in EMG reports and to develop standard guidelines for qualifying radiculopathies. Based on our observations, guidelines for the reporting of radiculopathies have been adopted in the Mayo Clinic Florida EMG laboratory. Muscle Nerve 49: 129–130, 2014.
36 min
April 10, 2014 Improving Referring Physicians' Understanding of EMG Reports When Qualifying Radiculopathies
Improving Referring Physicians' Understanding of EMG Reports When Qualifying Radiculopathies
36 min
March 10, 2014 Exome Sequencing by Michael Shy, MD and Stephan Zuchner, MD
Exome sequencing discussion by Michael Shy, MD and Stephan Zuchner, MD, and interviewed by Ted Burns, MD
46 min
December 20, 2013 Spinal muscular atrophy: development and implementation of potential treatments
Spinal muscular atrophy: development and implementation of potential treatments by Drs. David Arnold and Arthur Burghes and interviewed by Dr. Ted Burns. Ann Neurol. 2013 Sep;74(3):348-62. doi: 10.1002/ana.23995. This podcast is a brief discussion of the article in Annals in Neurology. The article discusses the rapid progress in the understanding of recessive proximal spinal muscular atrophy and how this is leading to exciting potential treatments of the disease. Spinal muscular atrophy is caused by loss of the survival motor neuron 1 (SMN1) gene and reduced levels of SMN protein. The critical downstream targets of SMN deficiency that result in motor neuron loss are not known. However, increasing SMN levels has a marked impact in mouse models, and these therapeutics are rapidly moving toward clinical trials. Promising preclinical therapies, the varying degree of impact on the mouse models, and potential measures of treatment effect are reviewed. One key issue discussed is the variable outcome of increasing SMN at different stages of disease progression.
43 min
December 20, 2013 Spinal muscular atrophy: development and implementation of potential treatments
Spinal muscular atrophy: development and implementation of potential treatments by Drs. David Arnold and Arthur Burghes and interviewed by Dr. Ted Burns. Ann Neurol. 2013 Sep;74(3):348-62. doi: 10.1002/ana.23995. This podcast is a brief discussion of the article in Annals in Neurology. The article discusses the rapid progress in the understanding of recessive proximal spinal muscular atrophy and how this is leading to exciting potential treatments of the disease. Spinal muscular atrophy is caused by loss of the survival motor neuron 1 (SMN1) gene and reduced levels of SMN protein. The critical downstream targets of SMN deficiency that result in motor neuron loss are not known. However, increasing SMN levels has a marked impact in mouse models, and these therapeutics are rapidly moving toward clinical trials. Promising preclinical therapies, the varying degree of impact on the mouse models, and potential measures of treatment effect are reviewed. One key issue discussed is the variable outcome of increasing SMN at different stages of disease progression.
43 min
December 19, 2013 Spinal muscular atrophy: Development and Implementation of Potential Treatments
Spinal muscular atrophy: Development and Implementation of Potential Treatments
43 min
November 27, 2013 Amyotrophic lateral sclerosis and palliative care: Where we are, and the road ahead by Dr. Blackhall
Amyotrophic lateral sclerosis and palliative care: Where we are, and the road ahead by Dr. Leslie J. Blackhall, interviewed by Dr. Michael K. Hehir. Patients with amyotrophic lateral sclerosis (ALS) have high symptom burdens, including pain, fatigue, dyspnea, and sialorrhea, and they must make difficult decisions about the use of life-prolonging therapies, such as long-term mechanical ventilation. The impact of ALS is also felt by family caregivers who often struggle to meet the heavy physical, financial, and emotional demands associated with the illness. Expert multidisciplinary care may improve both quality and length of life of patients with ALS. However, although advances have been made in the treatment of some symptoms, others, including pain management, remain poorly studied. Involvement of palliative care specialists as part of the ALS multidisciplinary team is recommended, as we continue to work toward improving the quality of life for patients and their families. Muscle Nerve, 2012. The ideas and opinions expressed are solely those of the specific authors and do not necessarily represent those of AANEM.
1 hr 9 min
November 21, 2013 Amyotrophic lateral sclerosis and palliative care: Where we are, and the road ahead by Dr. Blackhall
Amyotrophic lateral sclerosis and palliative care: Where we are, and the road ahead by Dr. Leslie J. Blackhall, interviewed by Dr. Michael K. Hehir. Patients with amyotrophic lateral sclerosis (ALS) have high symptom burdens, including pain, fatigue, dyspnea, and sialorrhea, and they must make difficult decisions about the use of life-prolonging therapies, such as long-term mechanical ventilation. The impact of ALS is also felt by family caregivers who often struggle to meet the heavy physical, financial, and emotional demands associated with the illness. Expert multidisciplinary care may improve both quality and length of life of patients with ALS. However, although advances have been made in the treatment of some symptoms, others, including pain management, remain poorly studied. Involvement of palliative care specialists as part of the ALS multidisciplinary team is recommended, as we continue to work toward improving the quality of life for patients and their families. Muscle Nerve, 2012. The ideas and opinions expressed are solely those of the specific authors and do not necessarily represent those of AANEM.
1 hr 9 min
August 30, 2013 Myasthenia Gravis and the use of IVIg and Therapeutic Plasma Exchange by Dr. Vern Juel
Myasthenia Gravis and the use of IVIg and Therapeutic Plasma Exchange by Dr. Vern Juel interviewed by Dr. Elliot Dimberg.
25 min
August 30, 2013 Myasthenia Gravis and the use of IVIg and Therapeutic Plasma Exchange by Dr. Vern Juel
Myasthenia Gravis and the use of IVIg and Therapeutic Plasma Exchange by Dr. Vern Juel interviewed by Dr. Elliot Dimberg.
25 min

About American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM)

From the publisher's feed

Hear from a variety of experts on all things neuromuscular & electrodiagnostic medicine. Learn new science, hear expert perspectives, and join the conversation!